Resmed INC Form 4 insider transactions

Michael J. Farrell, Chairman and CEO and a Director of Resmed Inc, sold 4,991 shares of common stock on October 7, 2026 for $226.33 per share.

Michael J. Farrell, Chairman and CEO and a Director of Resmed Inc, reported multiple transactions in common stock on September 8, 2026.

Justin Leong, Chief Product Officer of Resmed Inc, received 6,461 shares of common stock on August 14, 2026.

Michael J Rider, Global General Counsel of Resmed Inc, received 3,230 shares of common stock on August 14, 2026.

Michael J. Farrell, Chairman and CEO and a Director of Resmed Inc, received 13,547 shares of common stock on August 14, 2026.

Aaron Bloomer, Chief Financial Officer of Resmed Inc, received 9,072 shares of common stock on August 14, 2026.

Michael J. Farrell, Chairman and CEO and a Director of Resmed Inc, sold 4,991 shares of common stock on September 8, 2026 for $222.44 per share.

Peter C Farrell, a Director of Resmed Inc, sold 970 shares of common stock on September 2, 2026 for $234.73 per share.

Michael J. Farrell, Chairman and CEO and a Director of Resmed Inc, sold 4,991 shares of common stock on August 7, 2026 for $205.69 per share.

Peter C Farrell, a Director of Resmed Inc, sold 8,000 shares of common stock on August 5, 2026 for $225.00 per share.

ResMed CEO Michael Farrell executed a series of transactions involving the acquisition and disposition of company stock under a pre-arranged Rule 10b5-1 trading plan.

ResMed Inc. Chairman and CEO Michael J. Farrell reported the sale of 4,991 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

ResMed's Global General Counsel, Michael J. Rider, reported a disposition of company stock for tax withholding purposes related to vested Restricted Stock Units.

ResMed Inc. Chairman and CEO Michael Farrell reported transactions involving company stock, including acquisitions and dispositions, executed under a pre-arranged Rule 10b5-1 trading plan.

ResMed Inc. Chief Financial Officer Brett Sandercock has officially retired from his position effective May 4, 2026.

ResMed Chairman and CEO Michael Farrell executed a Rule 10b5-1 trading plan, acquiring 4,991 shares and selling 4,991 shares.

ResMed Inc. Chief Financial Officer Brett Sandercock executed a transaction involving 1,000 shares of common stock under a pre-established Rule 10b5-1 trading plan.

ResMed Chairman Emeritus Peter C. Farrell sold 2,000 shares of common stock at $225 per share via a 10b5-1 trading plan.

ResMed Director Peter C. Farrell sold 2,000 shares of common stock for $260.22 per share under a pre-arranged 10b5-1 trading plan.

ResMed Chairman and CEO Michael J. Farrell exercised stock options and subsequently sold an equal number of shares as part of a pre-arranged 10b5-1 trading plan.

ResMed Director Peter C. Farrell sold 2,000 shares of common stock for $251.31 per share, executed under a pre-arranged 10b5-1 plan.

ResMed's Global General Counsel, Michael J. Rider, executed a pre-scheduled sale of 50 common shares at $260 each on February 4, 2026.

ResMed Inc.'s Chief Financial Officer, Brett Sandercock, sold 1,000 shares of common stock for $257.03 per share as part of a pre-arranged trading plan.

ResMed Inc. Director Peter C. Farrell sold 2,000 shares of common stock for $248.83 per share, executed under a pre-arranged 10b5-1 trading plan.

ResMed Inc.'s Chairman and CEO, Michael J. Farrell, exercised options and sold 4,991 shares of common stock on January 7, 2026, under a pre-arranged 10b5-1 trading plan.

ResMed Inc.'s Chief Financial Officer, Brett Sandercock, sold 1,000 shares of common stock for $241.75 per share as part of a pre-arranged Rule 10b5-1 trading plan.

ResMed's Global General Counsel, Michael J. Rider, sold 50 shares of common stock for $241.75 per share under a pre-arranged 10b5-1 plan.

ResMed Inc. Chairman and CEO Michael J. Farrell sold 4,991 shares of common stock on December 8, 2025, following the exercise of options, under a Rule 10b5-1 plan.

ResMed Director Peter C. Farrell sold 2,000 shares of common stock for $251.47 per share under a pre-arranged 10b5-1 plan.

ResMed Inc.'s Global General Counsel, Michael J. Rider, reported the sale of 50 shares of common stock for $244.16 per share, executed under a pre-arranged Rule 10b5-1 trading plan.